Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19304415 | 0.85 | SLC6A3 (0.31) | CYP2A6TTRALB | |
| SCHEMBL12263154 | 0.79 | TTR (0.37) | CYP2A6TTRALBPGRGAA | |
| SCHEMBL15157794 | 0.79 | CYP2A6 (0.31) | CYP2A6TTRALBPGRGAA | |
| SCHEMBL12819962 | 0.77 | PKM (0.34) | GAAUSP2ALDH1A1PKMHPGD | |
| SCHEMBL19388475 | 0.77 | PKM (0.34) | GAAUSP2ALDH1A1PKMHPGD | |
| SCHEMBL18552812 | 0.77 | CYP2A6 (0.37) | CYP2A6GAASMN1; SMN2KCNK3 | |
| SCHEMBL27847325 | 0.76 | TTR (0.34) | TTRALBGAASMN1; SMN2 | |
| SCHEMBL26360496 | 0.76 | TTR (0.34) | TTRALBGAASMN1; SMN2 | |
| SCHEMBL17469351 | 0.75 | ALDH1A1 (0.41) | GAAUSP2ALDH1A1PKMHPGD | |
| SCHEMBL22166132 | 0.74 | PGR (0.37) | PGRGAAUSP2ALDH1A1PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2020-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10695337-B2 | Piperidin-4-yl azetidine derivatives as JAK1 inhibitors | JAK1, JAK2, JAK3 | CYP2A6 3258/4885TTR 4367/4885ALB 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.